Prosecution Insights
Last updated: April 19, 2026
Application No. 18/256,545

METHODS OF ADMINISTERING SYNTHETIC TRITERPENOIDS

Final Rejection §103
Filed
Jun 08, 2023
Examiner
SHIAO, REI TSANG
Art Unit
1691
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Reata Pharmaceuticals Holdings LLC
OA Round
2 (Final)
80%
Grant Probability
Favorable
3-4
OA Rounds
2y 3m
To Grant
45%
With Interview

Examiner Intelligence

Grants 80% — above average
80%
Career Allow Rate
1612 granted / 2019 resolved
+19.8% vs TC avg
Minimal -35% lift
Without
With
+-35.0%
Interview Lift
resolved cases with interview
Typical timeline
2y 3m
Avg Prosecution
53 currently pending
Career history
2072
Total Applications
across all art units

Statute-Specific Performance

§101
0.7%
-39.3% vs TC avg
§103
29.1%
-10.9% vs TC avg
§102
8.1%
-31.9% vs TC avg
§112
29.6%
-10.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 2019 resolved cases

Office Action

§103
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Priority and Status of Claims 1. This application is a CIP of PCT/US2021/072851 12/10/2021, , which claims benefit of the provisional application 63124677 12/11/2020. 2. Amendment of claims 1-2, 4, 8-9 and 15-20, and cancelation of claims 3, 5-7, 10-14, 21-49, 52-152, 183-184, 186, 188-191, 193-198 ad 200-203 in the amendment filed on 1/23/2026 is acknowledged. Claims 1-2, 4, 8-9, 15-20, 50-51, 153-182, 185, 187, 192 and 199 are pending in the application. Responses to Amendments/Arguments 3. Applicant's arguments regarding the rejection of claim 1 under 35 U.S.C. 103 (a) over Lynch et al. have been fully considered but they are not persuasive. Applicants state “Claim 1 of the previously pending claims was directed to methods of treating a patient having Friedreich's ataxia comprising administering a therapeutically effective amount of omaveloxolone, wherein the patient is further defined as not currently taking a cytochrome P450 3A4 (CYP3A4) modulator. Claim 1 has been amended with this response to further define the patient as in need of therapy with a drug that functions as a CYP3A4 modulator and the claimed methods as comprising avoiding or discontinuing concomitant use or co-administration of the drug that functions as a CYP3A4 modulator and the compound.”, see page 9. However, the instant claim 1 does not clearly limit the subpopulation of patients, who are previously or currently under an administration with CYP3A4 or with CYP3A4 and the instant compound omaveloxolone. Incorporation of the limitation of claim 2 into claim 1 would obviate the rejection. Claim Objections 4. Claims 2, 4, 8-9, 15-20, 50-51, 153-182, 185, 187, 192 and 199 are objected as being dependent on rejected claim 1. 5. THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to REI TSANG SHIAO whose telephone number is (571)272-0707. The examiner can normally be reached on 8:30 am-5:00 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Renee Claytor can be reached on 571-272-8394. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /REI TSANG SHIAO/ Rei-tsang Shiao, Ph.D.Primary Examiner, Art Unit 1691 March 09, 2026
Read full office action

Prosecution Timeline

Jun 08, 2023
Application Filed
Oct 20, 2025
Non-Final Rejection — §103
Jan 23, 2026
Response Filed
Mar 09, 2026
Final Rejection — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599580
COMPOSITION COMPRISING A LIPID COMPOUND, A TRIGLYCERIDE, AND A SURFACTANT, AND METHODS OF USING THE SAME
2y 5m to grant Granted Apr 14, 2026
Patent 12600719
SALT INDUCIBLE KINASE INHIBITORS
2y 5m to grant Granted Apr 14, 2026
Patent 12599579
COMPOSITIONS AND COMPOUNDS CONTAINNG KETONE BODIES AND/OR KETONE BODY PRECURSORS AND ONE OR MORE AMINO ACIDS
2y 5m to grant Granted Apr 14, 2026
Patent 12595556
MOLYBDENUM IMIDO ALKYL/ALLYL COMPLEXES FOR DEPOSITION OF MOLYBDENUM-CONTAINING FILMS
2y 5m to grant Granted Apr 07, 2026
Patent 12594254
INTRANASAL ADMINISTRATION OF N-ACETYLCYSTEINE AND USES THEREOF
2y 5m to grant Granted Apr 07, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

3-4
Expected OA Rounds
80%
Grant Probability
45%
With Interview (-35.0%)
2y 3m
Median Time to Grant
Moderate
PTA Risk
Based on 2019 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month